Phaseline

Targets › CIITA

CIITA (MHC class II transactivator): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.

Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,. Alternatively it may activate HLA class II transcription by…. (UniProt, P33076)

Open in Phaseline: the race on CIITA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCEx Vivo CRISPR-Cas9 Gene Editing of Donor Kidney
CRISPR-Cas9 ribonucleoprotein complexes targeting HLA-A, HLA-B, and CIITA to knock out HLA
HLA-A, HLA-B, CIITAPhase 1End-Stage Renal DiseaseDec 2027
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCEx Vivo CRISPR-Cas9 Gene Editing of Donor Liver
CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA to create hypoimmunogenic graft
HLA-A, HLA-B, CIITAPhase 1Liver DiseasesDec 2027

Conditions

End-Stage Renal Disease (1) Liver Diseases (1)

Modalities

other (2)

Companies

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC (2)

Related targets

HLA-A (2) HLA-B (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.